Headlands Technologies LLC Decreases Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)

Headlands Technologies LLC lessened its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 76.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,635 shares of the company’s stock after selling 5,199 shares during the quarter. Headlands Technologies LLC’s holdings in Krystal Biotech were worth $256,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of KRYS. Entropy Technologies LP purchased a new position in shares of Krystal Biotech in the 4th quarter valued at about $548,000. Janney Montgomery Scott LLC boosted its holdings in Krystal Biotech by 42.0% in the fourth quarter. Janney Montgomery Scott LLC now owns 52,592 shares of the company’s stock valued at $8,239,000 after purchasing an additional 15,545 shares in the last quarter. Principal Financial Group Inc. increased its stake in Krystal Biotech by 3.1% in the fourth quarter. Principal Financial Group Inc. now owns 123,453 shares of the company’s stock valued at $19,340,000 after purchasing an additional 3,727 shares during the last quarter. abrdn plc raised its holdings in Krystal Biotech by 32.5% during the fourth quarter. abrdn plc now owns 57,033 shares of the company’s stock worth $8,935,000 after purchasing an additional 13,979 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company’s stock worth $159,000 after buying an additional 433 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $171.30 on Friday. The stock has a fifty day moving average price of $173.27 and a 200 day moving average price of $173.18. Krystal Biotech, Inc. has a 1-year low of $141.72 and a 1-year high of $219.34. The company has a market cap of $4.93 billion, a PE ratio of 57.29 and a beta of 0.75.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. Krystal Biotech’s quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.30 EPS. Analysts anticipate that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the transaction, the insider now owns 1,463,711 shares of the company’s stock, valued at $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on KRYS shares. Citigroup increased their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Jefferies Financial Group began coverage on Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a research report on Friday, February 28th. Chardan Capital lifted their price target on Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).